Diagnostic platforms for a variety of applications

Formatted for any setting

Platforms

Now, more than ever, the world has become aware of the power of testing as a tool to access critical information about personal health.

Sherlock is enabling the democratization and decentralization of testing anywhere to personalize healthcare and to make an impact on global health.

Partner with us

We are partnering with diagnostic companies to enable the central lab, point-of-care and point-of-need markets, with pharmaceutical companies for decentralized clinical trial testing and diagnosis awareness, and with medical device companies to broaden device applications with our novel chemistries.

Sherlock’s Durable and Consumable devices

YOUR assay targets with our chemistry on our next generation devices

Sherlock’s CRISPR and synthetic biology technologies

Our assay chemistry for YOUR device

Global Health Partnerships

We partner with Global Health Institutions to bring diagnostic solutions to developing countries. Through our 221b Foundation we are further committed to developing, producing, and distributing easy to use and affordable diagnostics for infectious diseases affecting countries in the developing world. Contact us to discuss global health partnerships.

Inquire

Sherlock™ CRISPR-based chemistry is approved for clinical laboratory use

The Sherlock™ CRISPR-based SARS-CoV-2 kit was the very first FDA authorized CRISPR-based EUA diagnostic test for use in clinical laboratory settings

The Sherlock™ CRISPR-based SARS-CoV-2 kit is intended for the qualitative detection of nucleic acid from SARS-CoV-2. This test provides specific and sensitive detection of the SARS-CoV-2 virus in upper respiratory tract and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider.

Benefits

Faster than PCR; approximately 1 hour reaction time

Add thousands of tests per day to current lab volume

Highly specific and sensitive as demonstrated in EUA clinical evaluation and subsequent publication

Minimal footprint; uses standard laboratory equipment and a microplate reader

Proven highly sensitive with Limit of Detection comparable to RT-PCR

Safety, Legal, Quality, Usage Publications

More Info

Instructions for Use Our FAQ Fact Sheet for Healthcare Providers Fact Sheet for Patients

This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.